Last reviewed · How we verify
Oral Oxycodon
Oral Oxycodon, marketed by Max Dieterich, is an established opioid analgesic with a significant presence in the pain management market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. However, the primary risk lies in potential generic competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Oral Oxycodon |
|---|---|
| Sponsor | Max Dieterich |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pain and Medical Abortion Among Teenaged Women Compared to Adult Women (PHASE4)
- Superiority Study for Pain Treatment After Cesarean (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Oxycodon CI brief — competitive landscape report
- Oral Oxycodon updates RSS · CI watch RSS
- Max Dieterich portfolio CI